Neurological Involvements in COVID-19: A hospital-based study
Iranian Journal of Child Neurology,
Vol. 17 No. 3 (2023),
17 July 2023
,
Page 69-80
https://doi.org/10.22037/ijcn.v17i2.36829
Abstract
Objectives
The SARS-CoV-2 pandemic is the most challenging crisis in the contemporary world. Besides severe pulmonary involvement, the disease also has several extrapulmonary manifestations, and new signs and symptoms are associated with it every dayThe present study aimed to inquire about the frequency of neurological manifestations and risk factors of COVID-19.
Materials & Methods
This retrospective, descriptive study included patients with neurological involvement admitted to the Alborz University of Medical Sciences academic hospitals from March 2020 to July 2020 with confirmed COVID-19 infection. The data included in the analysis were the patient’s demographic information, underlying diseases, neurological manifestations, and laboratory findings.
Results
The study included ninety-five patients with a mean age of fiftynine. Neurological symptoms and signs were observed in 91.6% and 10.5% of the patients, respectively. The most frequently associated neurological symptoms of COVID-19 were fatigue (49.5%), headache (47.4%), and dizziness (45.3%). Furthermore, the most common neurological involvements included gait disorders (6.3%), cerebellar dysfunction (4.2%), and cerebrovascular accidents (3.15%). Positive troponin was shown to be the strongest predictor of neurological signs (OR=21, P=0.017), followed by WBC≥15,000 (OR = 20.75, P=0.018) and a history of respiratory disease (OR=7.42, P=0.007).
- COVID-19; Neurological Manifestations; SARS-CoV-2
How to Cite
References
2. Lim YX, Ng YL, Tam JP, Liu DX. Human Coronaviruses: A Review of Virus–Host Interactions. Diseases. 2016;4(3):26.
3. Smith RD. Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management. Soc Sci Med. 2006;63(12):3113-23.
4. Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. European review for medical and pharmacological sciences. 2018;22(15):4956-61.
5. Tadbiri H, Moradi-Lakeh M, Naghavi M. All-cause excess mortality and COVID-19-related deaths in Iran. Med J Islam Repub Iran. 2020;34(1):80.
6. https://covid19.who.int/table WACScNAf.
7. Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10(9):1550-7.
8. Stainsby B, Howitt S, Porr J. Neuromusculoskeletal disorders following SARS: a case series. The Journal of the Canadian Chiropractic Association. 2011;55(1):32-9.
9. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious diseases. 2013;13(9):752-61.
10. Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurological Complications during Treatment of Middle East Respiratory Syndrome. Journal of clinical neurology (Seoul, Korea). 2017;13(3):227-33.
11. Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clinical imaging. 2020;66:35-41.
12. Kalkeri R, Goebel S, Sharma GD. SARS-CoV-2 Shedding from Asymptomatic Patients: Contribution of Potential Extrapulmonary Tissue Reservoirs. The American journal of tropical medicine and hygiene. 2020;103(1):18-21.
13. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine. 2019;200(7):e45-e67.
14. Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer's research & therapy. 2020;12(1):1-3.
15. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England). 2020;395(10224):565-74.
16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020;395(10229):1054-62.
17. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90.
18. Correia AO, Feitosa PWG, de Sousa Moreira JL, Nogueira SÁR, Fonseca RB, Nobre MEP. Neurological manifestations of COVID-19 and other coronaviruses: a systematic review. Neurology, Psychiatry and Brain Research. 2020;37:27-32.
19. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020;77(6):683-90.
20. Favas T, Dev P, Chaurasia RN, Chakravarty K, Mishra R, Joshi D, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurological Sciences. 2020:1-34.
21. Kremer S, Lersy F, de Sèze J, Ferré J-C, Maamar A, Carsin-Nicol B, et al. Brain MRI findings in severe COVID-19: a retrospective observational study. Radiology. 2020;297(2):E242-E51.
22. Lechien JR, Chiesa‐Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild‐to‐moderate coronavirus disease 2019. Journal of internal medicine. 2020;288(3):335-44.
23. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: a systematic review and meta-analysis. International Journal of Stroke. 2021;16(2):137-49.
24. Qureshi AI, Baskett WI, Huang W, Shyu D, Myers D, Raju M, et al. Acute ischemic stroke and covid-19: An analysis of 27 676 patients. Stroke. 2021;52(3):905-12.
25. Annie F, Bates MC, Nanjundappa A, Bhatt DL, Alkhouli M. Prevalence and outcomes of acute ischemic stroke among patients≤ 50 years of age with laboratory confirmed COVID-19 infection. American Journal of Cardiology. 2020;130:169-70.
26. Mahammedi A, Saba L, Vagal A, Leali M, Rossi A, Gaskill M, et al. Imaging of neurologic disease in hospitalized patients with COVID-19: an Italian multicenter retrospective observational study. Radiology. 2020;297(2):E270-E3.
27. Carbo EC, Buddingh EP, Karelioti E, Sidorov IA, Feltkamp MC, Peter A, et al. Improved diagnosis of viral encephalitis in adult and pediatric hematological patients using viral metagenomics. Journal of Clinical Virology. 2020;130:104566.
28. Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clinical immunology (Orlando, Fla). 2007;123(3):258-67.
29. Jain R, Young M, Dogra S, Kennedy H, Nguyen V, Jones S, et al. COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. Journal of the neurological sciences. 2020;414:116923.
30. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 2020;95(8):e1060-e70.
31. Afshar H, Yassin Z, Kalantari S, Aloosh O, Lotfi T, Moghaddasi M, et al. Evolution and resolution of brain involvement associated with SARS-CoV2 infection: a close clinical–paraclinical follow up study of a case. Multiple sclerosis and related disorders. 2020;43:102216.
32. Tsivgoulis G, Palaiodimou L, Katsanos AH, Caso V, Köhrmann M, Molina C, et al. covid19?> Neurological manifestations and implications of COVID-19 pandemic. Therapeutic advances in neurological disorders. 2020;13:1756286420932036.
33. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clinical neurology and neurosurgery. 2020;194:105921.
34. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & nerve. 2020;62(4):485-91.
35. Archie SR, Cucullo L. Cerebrovascular and neurological dysfunction under the threat of COVID-19: is there a comorbid role for smoking and vaping? International journal of molecular sciences. 2020;21(11):3916.
36. Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke and vascular neurology. 2020;5(3).
37. Toljan K. Letter to the editor regarding the viewpoint “evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanism”. ACS chemical neuroscience. 2020;11(8):1192-4.
38. Mochan A, Modi G. Neurological involvement with COVID-19 review. Wits Journal of Clinical Medicine. 2020;2(2):135-40.
- Abstract Viewed: 244 times